Atea Pharmaceuticals, Inc. $AVIR

By Microcap Ledger desk · CIK 0001593899

Facts as of Oct 11, 2026, 08:07 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Global Select Market
Sector: Pharmaceutical Preparations
Headquarters: Boston, MA
Fiscal year end: December 31
Shares outstanding: 80,204,699 [10-Q 2026-08-12]
as of 2026-08-10

Sources: [10-K 2026-03-05]

What the company doesAI summary of filing

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral antiviral treatments for serious viral diseases. The company's lead program is a combination regimen of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV) infection, currently in Phase 3 clinical trials with topline results expected in mid-2026 and a planned FDA submission in March 2027. The company is also developing AT-587, a direct-acting antiviral for hepatitis E virus (HEV) infection in immunocompromised patients, with first-in-human studies anticipated to begin in mid-2026. Atea generates no product revenue and is dependent on the success of its clinical development programs. [10-K 2026-03-05]

Segments: Bemnifosbuvir and Ruzasvir (HCV), AT-587 (HEV)

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$78.37M	−$83.47M	$76.55M	[10-Q 2026-08-12]
FY ended Dec 2025	—	−$158.00M	−$132.03M	$95.71M	[DEF 14A 2026-04-27]
FY ended Dec 2024	—	−$168.00M	−$135.50M	$64.70M	[DEF 14A 2026-04-27]

Quarterly cash burn: −$41.74M
Cash runway Estimate: ~5.5 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-04	84,463,059	[10-Q 2024-11-07]
2025-03-04	85,525,179	[10-K 2025-03-06]
2025-05-09	85,579,475	[10-Q 2025-05-12]
2025-08-04	79,357,553	[10-Q 2025-08-07]
2025-11-10	78,126,796	[10-Q 2025-11-12]
2026-03-04	79,672,083	[10-K 2026-03-05]
2026-05-11	80,027,099	[10-Q 2026-05-12]
2026-08-10	80,204,699	[10-Q 2026-08-12]

Shelf registration: S-3 filed 2024-11-07; declared effective 2024-11-19 [S-3 2024-11-07]

Listing status

Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-06-18	Lucidi Bruno	exercise	29,600	—	[4 2026-06-23]
2026-06-18	Berger Franklin M	exercise	29,600	—	[4 2026-06-23]
2026-06-18	Duncan Barbara Gayle	exercise	29,600	—	[4 2026-06-23]
2026-06-18	Polsky Bruce	exercise	29,600	—	[4 2026-06-23]
2026-06-18	Murphy Polly A.	exercise	29,600	—	[4 2026-06-23]
2026-06-18	Adams Jerome M.	exercise	29,600	—	[4 2026-06-23]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-10-06	13G	Beneficial ownership report (5%+ holder)
2026-08-12	10-Q	Quarterly report
2026-08-12	8-K	Results of operations
2026-06-22	8-K	Shareholder vote results
2026-05-12	10-Q	Quarterly report
2026-05-12	8-K	Results of operations
2026-05-06	13G/A	Beneficial ownership report (5%+ holder)
2026-04-27	DEF 14A	Proxy statement
2026-03-26	13G/A	Beneficial ownership report (5%+ holder)
2026-03-05	10-K	Annual report
2026-03-05	8-K	Results of operations
2026-02-09	13G	Beneficial ownership report (5%+ holder)

Facts as of Oct 11, 2026, 08:07 AM UTC. Small caps move fast; check the latest filings.